Abstract: The present invention relates to a novel immunoglobulin Fc domain variant protein and use thereof, and when expressed in the form of a fusion protein with another biologically active protein, an immunoglobulin Fc domain variant protein according to an embodiment of the present invention can prolong the half-life in vivo of the biologically active protein as well as effectively suppress effector functions such as ADCC or CDC to minimize unexpected side effects.

Abstract: A treatment of cervical tumor caused by human papillomavirus (HPV) infection is disclosed. Methods for improving treatment of cervical tumor caused by HPV infection are also disclosed. The methods include administering a polynucleotide encoding an E6/E7 fusion protein to a subject suffering from cervical tumor caused by HPV. The cervical tumor may be squamous cell carcinoma (SCC), adenocarcinoma, adenosquamous carcinoma, small cell carcinoma, neuroendocrine tumor (NET), glassy cell carcinoma, villoglandular adenocarcinoma (VGA), non-carcinoma malignancies, melanoma, lymphoma, or cervical intraepithelial neoplasia (CIN).

Abstract: This invention relates to the treatment of cervical tumor caused by human papillomavirus (HPV) infection. In particular, the invention provides methods for improving cervical tumor treatment and methods for treating cervical tumor caused by HPV infection using a polynucleotide encoding an E6/E7 fusion protein.

Abstract: Provided is a gene vaccine composition for preventing and treating severe fever with thrombocytopenia syndrome (SFTS), including, as an active ingredient, at least one expression vector including a first polynucleotide encoding a glycoprotein N (Gn) derived from SFTS virus, a second polynucleotide encoding a glycoprotein C (Gc), a third polynucleotide encoding a nucleocapsid protein (NP) derived from the SFTS virus, and a fourth polynucleotide encoding a nonstructural protein (NS) derived from the SFTS virus.

Abstract: This invention relates to the treatment of cervical tumor caused by human papillomavirus (HPV) infection. In particular, the invention provides methods for improving cervical tumor treatment and methods for treating cervical tumor caused by HPV infection using a polynucleotide encoding an E6/E7 fusion protein.

Abstract: The present invention relates to a fusion protein comprising a fusion polypeptide of E6 and E7 of a human papilloma virus, a signal peptide for secreting the polypeptide out of the cell, and an immune enhancing peptide for a subject; a polynucleotide encoding the fusion protein; and a vector containing the polynucleotide. The present invention further relates to a pharmaceutical composition comprising the fusion protein or the vector; and a method for treating a disease caused by a human papilloma virus using the pharmaceutical composition.

Abstract: The present invention relates to a fusion protein comprising a fusion polypeptide of E6 and E7 of a human papilloma virus, a signal peptide for secreting the polypeptide out of the cell, and an immune enhancing peptide for a subject; a polynucleotide encoding the fusion protein; and a vector containing the polynucleotide. The present invention further relates to a pharmaceutical composition comprising the fusion protein or the vector; and a method for treating a disease caused by a human papilloma virus using the pharmaceutical composition.

Abstract: The present invention relates to a fusion protein comprising a fusion polypeptide of E6 and E7 of a human papilloma virus, a signal peptide for secreting the polypeptide out of the cell, and an immune enhancing peptide for a subject; a polynucleotide encoding the fusion protein; and a vector containing the polynucleotide. The present invention further relates to a pharmaceutical composition comprising the fusion protein or the vector; and a method for treating a disease caused by a human papilloma virus using the pharmaceutical composition.